The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.

The fortunes of RLY-2608 reverse, and a pivotal study will follow.

Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.

Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.

The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.

The depressed company could use Mylotarg as a stepping stone in AML.

After Niagara the company faces three pivotal catalysts; none is a slam-dunk.

The group eyes a broader use than Immunocore’s Kimmtrak.

An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.

A macrocycle-based therapy enters the clinic, as do projects targeting p53 interaction and IL-12.